Insight

Jordi Remon: Unresolved challenges with ICB and TKIs for early stage NSCLC

Photo taken from Jordi Remon/X

Aug 9, 2024, 14:55

Jordi Remon: Unresolved challenges with ICB and TKIs for early stage NSCLC

Jordi Remon, a Thoracic oncologist at CIOCC Barcelona, recently posted on X:

“In the current landscape treatments for early stage NSCLC several challenges with immunotherapy (ICB) and TKIs remain unresolved.We describe current data and challenges in this setting: role ICB in stage II or PDL1<1%,adjuvant TKI for all?.

Thanks to all authors!”

unresolved

Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies

Autors: Pernelle Lavaud, Martina Bortolot, Lodovica Zullo, David O’Reilly, Jarushka Naidoo, Giannis Mountzios, Olaf Mercier, Lizza E. L. Hendriks, Jordi Remon

unresolved

Source: Jordi Remon/X

cancer David O’Reilly Giannis Mountzios Jarushka Naidoo Jordi Remon Lizza E. L. Hendriks Lodovica Zullo Martina Bortolot Olaf Mercier OncoDaily Oncology Pernelle Lavaud

Bernard Fox received SITC lifetime achievement award

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Special Coverage